Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Kaplan Fox & Kilsheimer LLPKaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (FULC) to a Securities Law InvestigationKaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also contact...
- Robbins LLPRobbins LLP Reminds REGN Stockholders of the Pending Lead Plaintiff Deadline in the Class Action Against Regeneron Pharmaceuticals, Inc.Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the "Class Period").The lawsuit alleges that Regeneron Pharmaceuticals misled investors regarding the viability and prospects of its Phase 3 Fianlimab-Libtayo clinical trial for patients with...
- JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in DermatomyositisPriovant Therapeutics announced today the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in adults with dermatomyositis (DM). Primary efficacy and safety results from the trial were previously published in the New England Journal of Medicine, including benefit on measures of skin disease, muscle strength, physical function, and steroid-sparing.
- Cizzle BioCizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx SummitMoffitt Cancer Center's Dr. Lary Robinson discusses blood-based biomarkers in early lung cancer detection and ongoing CIZ1B clinical study — Cizzle Bio Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, today...
- Thyme CareThyme Care Earns NCQA Accreditation for Both Its Cancer Case Management and Population Health ProgramsNCQA evaluated Thyme Care's cancer programs against two separate sets of national standards, covering care planning and monitoring, data integration, staff licensure and training. — Thyme Care, the oncology company aligning accountability...
- Faruqi & Faruqi LLPFaruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class ActionFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Regeneron to Contact Him Directly to Discuss Their OptionsNew York, New York--(August 26, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of a Securities Class Action Deadline on October 5, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by...
- ViiV HealthcareU.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young childrenLONDON, August 26, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir (DTG)), for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in paediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor (INSTI)-naïve) weighing at least 2 kg.
- Agenus Inc.Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon CancerLEXINGTON, Mass., August 26, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, and balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable colon cancer. The manuscript, titled "Neoadjuvant botensilimab/balstilimab for localized mismatch re
- Faruqi & Faruqi LLPFaruqi & Faruqi, LLP Urges Capricor Therapeutics, Inc. (CAPR) Investors to Seek Counsel Before the September 28, 2026 Lead Plaintiff Deadline in the Securities Class ActionFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Capricor to Contact Him Directly to Discuss Their OptionsNew York, New York--(August 26, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the September 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Capricor Therapeutics, Inc. ("Capricor" or the...
- Faruqi & Faruqi LLPFaruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class ActionFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in ARS Pharmaceuticals to Contact Him Directly to Discuss Their OptionsNew York, New York--(August 26, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against ARS Pharmaceuticals Inc. (""ARS Pharmaceuticals"...
- Candel TherapeuticsCandel Therapeutics to Present at September Investor ConferencesCandel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026.